Inhibition and induction of CYP enzymes in humans : an update
|Author:||Hakkola, Jukka1,2,3; Hukkanen, Janne2,4; Turpeinen, Miia1,5;|
1Research Unit of Biomedicine, Pharmacology and Toxicology, University of Oulu, POB 5000, 90014, Oulu, Finland
2Biocenter Oulu, University of Oulu, Oulu, Finland
3Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland
4Research Unit of Internal Medicine, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland
5Administration Center, Medical Research Center Oulu, University of Oulu and Oulu University Hospital, Oulu, Finland
|Online Access:||PDF Full Text (PDF, 1.3 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2020112492766
|Publish Date:|| 2020-11-24
The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies and toxic compounds in the environment. The inhibition and induction of CYPs are major mechanisms causing pharmacokinetic drug–drug interactions. This review presents a comprehensive update on the inhibitors and inducers of the specific CYP enzymes in humans. The focus is on the more recent human in vitro and in vivo findings since the publication of our previous review on this topic in 2008. In addition to the general presentation of inhibitory drugs and inducers of human CYP enzymes by drugs, herbal remedies, and toxic compounds, an in-depth view on tyrosine-kinase inhibitors and antiretroviral HIV medications as victims and perpetrators of drug–drug interactions is provided as examples of the current trends in the field. Also, a concise overview of the mechanisms of CYP induction is presented to aid the understanding of the induction phenomena.
Archives of toxicology
|Pages:||3671 - 3722|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
Open access funding provided by University of Oulu including Oulu University Hospital. The original research by the authors is supported by the Academy of Finland (Grants 286743 and 323706) to JHa, Finnish Medical Foundation; the Finnish Foundation for Cardiovascular Research; the Northern Finland Health Care Support Foundation; and the Diabetes Research Foundation to JHu, the Northern Finland Health Care Support to MT.
|Academy of Finland Grant Number:||
286743 (Academy of Finland Funding decision)
323706 (Academy of Finland Funding decision)
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.